CIPLA PACLITAXEL Paclitaxel (nanoparticle albumin-bound) 100 mg powder for injection (suspension) vial

국가: 오스트레일리아

언어: 영어

출처: Department of Health (Therapeutic Goods Administration)

유효 성분:

paclitaxel, Quantity: 100 mg

제공처:

Cipla Australia Pty Ltd

약제 형태:

Injection, powder for

구성:

Excipient Ingredients: Albumin; N-acetyl-dl-tryptophan; sodium octanoate

관리 경로:

Intravenous

패키지 단위:

1 x 50 mL vial

처방전 유형:

(S4) Prescription Only Medicine

치료 징후:

Metastatic breast cancer: Cipla Paclitaxel is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. Non-small Cell Lung Cancer: Cipla Paclitaxel, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation. Metastatic Adenocarcinoma of the Pancreas: Cipla Paclitaxel, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.

제품 요약:

Visual Identification: Nano-paclitaxel injection is a sterile white to yellow lyophilized cake or powder in a 50 mL USP Type I flint glass vial.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

승인 상태:

Registered

승인 날짜:

2020-10-29